创新医疗管理股份有限公司董事会决议公告详解
一、会议召开情况
创新医疗管理股份有限公司于2026年4月28日召开第七届董事会第二次临时会议。此次会议以通讯表决方式进行，会议通知于2026年4月24日以书面形式发出。会议由董事长陈海军主持，9名董事全部出席，公司高级管理人员亦列席。会议符合法律及公司章程规定，合法有效。
二、主要决议及对股东的影响
- 2026年第一季度报告审议通过： 董事会全票通过了《2026年第一季度报告》。虽然公告未披露具体报告内容，但该报告一般包含公司财务状况、经营成果及未来展望，投资者可关注后续公开的详细财报，判断公司盈利能力及发展前景。
- 为浙江鸿润医药有限公司提供担保： 公司决定为浙江鸿润医药有限公司在800万元授信额度内，向招商银行绍兴诸暨支行申请贷款提供担保。这意味着创新医疗将承担一定财务风险。此举有利于保障鸿润医药业务发展，但公司需关注担保事项对自身财务状况的影响，尤其是担保规模、被担保企业的偿付能力等。任何担保事项都可能影响公司资产负债表，若鸿润医药出现违约，将对创新医疗产生负面影响，可能引发股价波动。
三、对投资者的提示
此次公告涉及公司对外担保事项，属于重大经营决策。投资者需关注公司后续相关信息披露，尤其是被担保企业的经营情况及公司季度报告的具体内容。此外，担保事项若产生负面影响，可能对公司股价造成压力。
四、相关文件备查
公司已保存《第七届董事会2026年第二次临时会议决议》相关文件，投资者可进一步查阅详情。
免责声明
本文章基于公司公开信息整理，仅供参考，不构成任何投资建议。投资者应结合自身情况和更多公开信息，谨慎决策。公司公告内容如有更新，请以官方公告为准。
Detailed Analysis of Innovate Medical Management Co., Ltd. Board Resolution Announcement
1. Meeting Details
Innovate Medical Management Co., Ltd. held the second interim meeting of its seventh board on April 28, 2026. The meeting was conducted via a written communication vote, with the notice sent out on April 24, 2026. Chairman Chen Haijun presided, with all 9 directors in attendance and senior management present. The meeting complied with all legal and statutory requirements.
2. Key Resolutions and Potential Impact on Shareholders
- Approval of Q1 2026 Report: The board unanimously approved the 2026 Q1 report. Although specifics are not disclosed in the announcement, this report typically covers the company’s financial and operational performance, as well as future outlook. Investors should look out for the detailed financials for insights on profitability and growth prospects.
- Guarantee for Zhejiang Hongrun Pharmaceutical: The company resolved to provide a guarantee for Zhejiang Hongrun Pharmaceutical Co., Ltd. for a loan application within an RMB 8 million credit line at China Merchants Bank Shaoxing Zhuji Branch. This exposes Innovate Medical to financial risk, as it will bear responsibility if Hongrun Pharmaceutical defaults. While the aim is to support Hongrun’s business development, investors should monitor the impact of this guarantee on Innovate Medical’s financials, especially the size of the guarantee and Hongrun’s ability to repay. Guarantee-related risks can affect the company’s balance sheet and may trigger share price volatility if negative developments occur.
3. Investor Advisory
The guarantee represents a significant operational decision and potential liability. Investors should closely monitor further disclosures, especially Hongrun Pharmaceutical’s performance and the detailed quarterly report. Any adverse developments related to the guarantee may affect share prices.
4. Reference Documents
The company has preserved the resolution documents from the meeting, available for further review.
Disclaimer
This article is based on public disclosures and is for informational purposes only. It does not constitute investment advice. Investors are encouraged to make decisions cautiously and refer to official documents for updated information.
View 创新医疗 Historical chart here
